| [1] | Abdill R.J., Graham S.P., Rubinetti V., et al. (2025). Integration of 168,000 samples reveals global patterns of the human gut microbiome. Cell 188:1100−1118.e1117. DOI:10.1016/j.cell.2024.12.017 |
| [2] | Lin N.Y., Fukuoka S., Koyama S., et al. (2025). Microbiota-driven antitumour immunity mediated by dendritic cell migration. Nature 644:1058−1068. DOI:10.1038/s41586-025-09249-8 |
| [3] | Wu G., Xu T., Zhao N., et al. (2024). A core microbiome signature as an indicator of health. Cell 187:6550−6565.e6511. DOI:10.1016/j.cell.2024.09.019 |
| [4] | Qu R., Zhang Y., Kim B., et al. (2025). Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression. Cell Metab. 37:1852−1869.e1858. DOI:10.1016/j.cmet.2025.06.002 |
| [5] | Zhang F., Zuo T., Wan Y., et al. (2022). Multi-omic analyses identify mucosa bacteria and fecal metabolites associated with weight loss after fecal microbiota transplantation. The Innovation 3:100304. DOI:10.1016/j.xinn.2022.100304 |
| Qu R., Weng J., Yang Q., et al. (2026). New framework for precision clinical translation of gut microbiota in cancer: From individual variation to functional universality. The Innovation Oncology 1:100015. https://doi.org/10.59717/j.xinn-oncol.2026.100015 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
A new framework for precision clinical translation of gut microbiota in cancer